for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

SCYNEXIS Inc

SCYX.OQ

Latest Trade

1.17USD

Change

0.02(+1.30%)

Volume

32,258

Today's Range

1.15

 - 

1.20

52 Week Range

0.36

 - 

1.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.15
Open
1.16
Volume
32,258
3M AVG Volume
5.25
Today's High
1.20
Today's Low
1.15
52 Week High
1.90
52 Week Low
0.36
Shares Out (MIL)
55.71
Market Cap (MIL)
64.06
Forward P/E
-1.19
Dividend (Yield %)
--

Latest Developments

More

Scynexis Reports Q2 Loss Per Share $0.16

Scynexis Announces Special Protocol Assessment (SPA) Agreement With FDA For Phase 3 Study Evaluating Oral Ibrexafungerp

Scynexis Q1 Loss Per Share $0.46

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About SCYNEXIS Inc

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

Industry

Biotechnology & Drugs

Contact Info

1 Evertrust Plz Fl 13

+1.201.8845485

http://www.scynexis.com/

Executive Leadership

Pamela J. Kirby

Chairman of the Board

Marco Taglietti

President, Chief Executive Officer, Director

Eric S. Francois

Chief Financial Officer

Nkechi Azie

Vice President - Clinical Development

Scott A. Sukenick

General Counsel

Key Stats

1.63 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.580

2017

-0.940

2018

-0.280

2019(E)

-0.966
Price To Earnings (TTM)
--
Price To Sales (TTM)
257.29
Price To Book (MRQ)
6.03
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
140.28
LT Debt To Equity (MRQ)
140.28
Return on Investment (TTM)
-73.72
Return on Equity (TTM)
-58.55

Latest News

BRIEF-Scynexis Q1 Loss Per Share $0.12

* SCYNEXIS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

BRIEF-Caxton Corporation Reports 9.99 Percent Passive Stake In Scynexis Inc As Of March 6, 2018 - SEC Filing

* CAXTON CORPORATION REPORTS 9.99 PERCENT PASSIVE STAKE IN SCYNEXIS INC AS OF MARCH 6, 2018 - SEC FILING Source text (http://bit.ly/2tII9WD) Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-SCYNEXIS Announces Pricing Of $30 Mln Public Offering Of Common Stock And Warrants

* SCYNEXIS ANNOUNCES PRICING OF $30.0 MILLION PUBLIC OFFERING OF COMMON STOCK AND WARRANTS

BRIEF-Scynexis Inc Presents New In Vivo Data Highlighting The Potential Of Scy-078

* SCYNEXIS PRESENTS NEW IN VIVO DATA HIGHLIGHTING THE POTENTIAL OF SCY-078 USED IN COMBINATION FOR THE TREATMENT OF ASPERGILLUS INFECTIONS AT AAA 2018 Source text for Eikon: Further company coverage:

BRIEF-Scynexis Provides Corporate And SCY-078 Pipeline Update

* SCYNEXIS INC - INTENDS TO INITIATE A PHASE 1 STUDY IN HEALTHY VOLUNTEERS IN Q3 2018, PENDING FDA'S REVIEW FOR LIPOSOMAL IV FORMULATION OF SCY-078

BRIEF-Scynexis reports third quarter 2017 financial results

* Scynexis reports third quarter 2017 financial results and provides company update

BRIEF-Scynexis presents new data related to SCY-078​

* Scynexis Inc - data demonstrates broad activity and potential clinical utility of SCY-078 against invasive candida and aspergillus infections Source text for Eikon: Further company coverage:

BRIEF-Scynexis CEO Marco Taglietti​ buys 10,000 shares of co's common stock on Aug 15

* Scynexis Inc CEO Marco Taglietti reports purchase of 10,000 shares of co's common stock on Aug 15 at $1.61 per share - SEC filing Source text: (http://bit.ly/2wj4Cck) Further company coverage:

BRIEF-Scynexis Q2 loss per share $0.16

* Scynexis reports second quarter 2017 financial results and provides company update

BRIEF-SCYNEXIS announces initiation of dosing in Phase 2 study evaluating oral SCY-078 in Vulvovaginal Candidiasis

* SCYNEXIS announces initiation of dosing in Phase 2 study evaluating oral SCY-078 in Vulvovaginal Candidiasis

BRIEF-Scynexis Q1 loss per share $0.19

* Scynexis reports first quarter 2017 financial results and provides update on iv formulation development status

BRIEF-Scynexis says to present SCY-078 data on lead anti-infective candidate

* Scynexis inc says to present scy-078 data on novel lead anti-infective candidate

BRIEF-Scynexis announces appointment Marion Mccourt to its board

* Scynexis announces appointment of industry veteran Marion Mccourt to its board of directors

BRIEF-SCYNEXIS Inc reports Q3 2016 financial results

* SCYNEXIS, Inc. reports third quarter 2016 financial results and provides company update

BRIEF-SCYNEXIS: HC Wainwright starts with $14 PT; rating 'buy'

* HC Wainwright starts with $14 price target; rating buy Further company coverage:

BRIEF-Scynexis enters into loan and security agreement with Solar Capital

* On September 30, 2016, Co entered into loan and security agreement with Solar Capital Ltd. - SEC filing

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up